<DOC>
	<DOC>NCT02201849</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, and pharmacokinetics of ALKS 8700, a monomethyl fumerate (MMF) molecule.</brief_summary>
	<brief_title>A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Has a bodymass Index (BMI) &gt;/=18.0 and &lt;/=32.0 kg/m2 Agrees to use an acceptable method of contraception for the duration of the study and for 30 days after any study drug administration Additional criteria may apply Is currently pregnant or breastfeeding Has a lifetime history of menopausal hot flashes Has a clinically significant medical condition Has had a clinically significant illness in the 30 days prior to first study drug administration Has had a serious infection (eg, pneumonia or septicemia) within the 3 months prior to study drug administration Has had any vaccinations in the 4 weeks prior to inpatient admission Has a lifetime history of diabetes Additional criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>ALKS 8700</keyword>
</DOC>